Responsibilities
- Work collaboratively with the Chief Operating Officer and Operations leadership to provide financial support and business partnering for the Operations organization
- Manage all aspects of FP&A for Operations, such as forecasting, monthly budget vs. actual, and analysis
- Provide insights into key opportunities and profitability for potential projects to ensure each is financially viable and aligns with the company’s strategic goals
- Develop and maintain the manning plan for our manufacturing sites to ensure gross margin targets are achieved and drive cost improvement projects to improve gross margins over time
- Support the creation of business and financial presentations (e.g., board decks, Quarterly Business Reports, etc.) for Operations-related activities
- Establish and lead Operations Finance teams at our manufacturing site in Bridgewater, Europe, and Japan
- As part of the Company’s annual audit process, prepare supporting and supplemental information as requested by the Company’s auditors, as it relates to Operations
Requirements
- Bachelor’s degree in finance, accounting, or a related field
- 10+ years of relevant demonstrated financial and leadership experience
- Extensive experience with SAP or other relevant ERP solutions
- Experience with analysis tools and databases such as SQL, Power Query, Power BI, Snowflake, and Tableau
- Highly organized with a meticulous attention to detail and the willingness to be in a hands-on position
- Deep understanding of industry financials
- Proven track record of financial leadership in a fast-paced, dynamic environment
- Strong analytical and problem-solving skills, with the ability to synthesize complex information into clear recommendations
- Excellent communication and interpersonal skills, with the ability to work effectively with both internal teams and external partners
Top Skills
What We Do
Cellares is revolutionizing cell therapy manufacturing. We are developing a one-of-a-kind solution, The Cell Shuttle, to overcome the challenges associated with manufacturing so these life-saving therapies are affordable and widely available to patients who can benefit. The clinical impact of cell therapy in treating cancer has been proven, but this therapeutic approach has several limitations, especially in manufacturing, leaving extremely sick patients waiting for treatment and desperate for hope. Since cell therapy is currently produced for a single patient at a time, it is expensive to manufacture, requiring significant time and resources, and is difficult to scale. Preclinical and clinical scientists, as well as commercial cell therapy manufacturers also lack the options to fully automate their manufacturing process quickly, safely, cost-effectively and at the scale they need. The Cell Shuttle is an automated and closed end-to-end manufacturing solution that is flexible and scalable, enabling customers to run exact processes specified for their cell therapy. Compared with the current manual manufacturing processes for cell therapy, the Cell Shuttle’s next-generation automated manufacturing solution has 10 times the scalability (meaning 10 times more patient doses can be produced simultaneously), enables a three-fold reduction in process failure rates and will reduce the per-patient manufacturing cost by up to 70 percent for most processes.
.png)
